New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis.

Pharmaceuticals
Sarentha ChettyNeil R Thomas

Abstract

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has reinforced the need for the development of new anti-TB drugs. The first line drug isoniazid inhibits InhA. This is a prodrug requiring activation by the enzyme KatG. Mutations in KatG have largely contributed to clinical isoniazid resistance. We aimed to design new 'direct' InhA inhibitors that obviate the need for activation by KatG, circumventing pre-existing resistance. In silico molecular modelling was used as part of a rational structure-based drug-design approach involving inspection of protein crystal structures of InhA:inhibitor complexes, including the broad spectrum antibiotic triclosan (TCS). One crystal structure exhibited the unusual presence of two triclosan molecules within the Mycobacterium tuberculosis InhA binding site. This became the basis of a strategy for the synthesis of novel inhibitors. A series of new, flexible ligands were designed and synthesised, expanding on the triclosan structure. Low Minimum Inhibitory Concentrations (MICs) were obtained for benzylphenyl compounds (12, 43 and 44) and di-triclosan derivative (39), against Mycobacterium bovis BCG although these may also be inhibiting other enzymes...Continue Reading

References

Apr 4, 1997·Journal of Molecular Biology·G JonesR Taylor
Apr 10, 1999·The Journal of Biological Chemistry·R J HeathC O Rock
Oct 10, 2001·Progress in Lipid Research·R J HeathC O Rock
Feb 28, 2003·The Journal of Biological Chemistry·Mack R KuoDavid A Fidock
Jul 23, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Li-Quan WangMargaret O James
Dec 14, 2004·Journal of Medicinal Chemistry·Jared T SpletstoserGunda I Georg
Nov 1, 2006·Molecular Microbiology·Graham S Timmins, Vojo Deretic
Feb 13, 2007·Bioorganic & Medicinal Chemistry·Yves L Janin
May 7, 2008·Bioorganic & Medicinal Chemistry Letters·Christopher W am EndePeter J Tonge
Jun 10, 2008·European Journal of Medicinal Chemistry·Suvarna G KiniFranck E Dayan
Nov 6, 2008·Chemical Communications : Chem Comm·William C Drewe, Stephen Neidle
Mar 5, 2010·The Journal of Biological Chemistry·Sylvia R LucknerCaroline Kisker
Apr 20, 2010·Methods in Molecular Biology·Dimitrios Evangelopoulos, Sanjib Bhakta
May 7, 2010·Journal of Enzyme Inhibition and Medicinal Chemistry·Suvarna G KiniFranck E Dayan
Dec 27, 2011·Bioorganic & Medicinal Chemistry Letters·Yinghong YangYuquan Wei
Jan 31, 2012·Current Topics in Medicinal Chemistry·Pan Pan, Peter J Tonge
Sep 20, 2015·Journal of Molecular Graphics & Modelling·Sanchaita RajkhowaRamesh Chandra Deka
Oct 16, 2015·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·Y Zhang, W-W Yew
Aug 4, 2016·Drug Design, Development and Therapy·Sidhartha S KarG Gautham Shenoy
Sep 25, 2016·Drug Discovery Today·Kaja RožmanLourdes Encinas
Dec 27, 2017·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Rudolf VosátkaJarmila Vinšová

❮ Previous
Next ❯

Software Mentioned

ExPasy translate
SYBYL X
Genetic Optimization for Ligand Docking ( GOLD )
ACD Labs
Molinspiration Cheminformatics server
Tripos

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
Rudolf VosátkaJarmila Vinšová
© 2021 Meta ULC. All rights reserved